<DOC>
	<DOC>NCT02305329</DOC>
	<brief_summary>Single-centre, open-label, randomized, two-sequence, two-way crossover study. The study consisted of two consecutive single-dose treatment periods separated by a washout period of 10 to 14 days or more.</brief_summary>
	<brief_title>Dosage Form Proportionality of Opicapone To-Be-Marketed Formulation</brief_title>
	<detailed_description>Single-centre, open-label, randomized, two-sequence, two-way crossover study. The study consisted of two consecutive single-dose treatment periods separated by a washout period of 10 to 14 days or more. In Group 1 the volunteers received a single oral dose of 25 mg OPC. In Group 2 the volunteers received a single oral dose of 50 mg OPC</detailed_description>
	<mesh_term>Opicapone</mesh_term>
	<criteria>Male or female subjects aged 18 to 45 years, inclusive; Body mass index (BMI) between 19 and 30 kg/m²; Healthy as determined by prestudy medical history, physical examination, vital signs, complete neurological examination, and 12lead ECG; Negative tests for hepatitis B surface antigen (HBsAg), antihepatitis C vírus (antiHCV) antibodies, and antihuman immunodeficiency virus (HIV)1/2 antibodies at screening; Clinical laboratory test results clinically acceptable at screening and admission to each treatment period; Negative screen for alcohol and drugs of abuse at screening and admission to each treatment period; Nonsmokers or exsmokers for at least 3 months; Able and willing to give written informed consent; If female: She was not of childbearing potential by reason of surgery or, if of childbearing potential, she used an effective nonhormonal method of contraception (intrauterine device or intrauterine system; condom or occlusive cap [diaphragm or cervical or vault caps] with spermicidal foam or gel or film or cream or suppository; true abstinence; or vasectomized male partner, provided that he was the sole partner of that subject) for all the duration of the study; and she had a negative serum pregnancy test at screening and a negative urine pregnancy test on Day 1 of each treatment period. A clinically relevant history or presence of respiratory, gastrointestinal, renal, hepatic, haematological, lymphatic, neurological, cardiovascular, psychiatric, musculoskeletal, genitourinary, immunological, dermatological, endocrine, connective tissue diseases or disorders; A clinically relevant surgical history; Any clinically relevant abnormality in the coagulation tests; Any clinically relevant abnormality in the liver function tests. If the subject had a borderline clinically relevant abnormality that was not considered clinically significant, a retest could be done after discussion with the sponsor's medical monitor; A history of relevant atopy or drug hypersensitivity; A history of alcoholism or drug abuse; Consume more than 14 units of alcohol a week; A significant infection or known inflammatory process on screening or admission to each treatment period; Acute gastrointestinal symptoms (e.g., nausea, vomiting, diarrhoea, heartburn) at the time of screening or admission to each treatment period; Used medicines within 2 weeks of admission to first period that could have affected the subject's safety or other study assessments in the investigator's opinion; Previously received OPC. Previous use of OPC was documented by questioning the subjects; Used any investigational drug or participated in any clinical trial within 90 days prior to screening Participated in more than 2 clinical trials within the 12 months prior to screening; Donated or received any blood or blood products within the 3 months prior to screening; Vegetarians, vegans or have medical dietary restrictions; Not able to communicate reliably with the investigator; Unlikely to cooperate with the requirements of the study; unwilling or unable to give written informed consent; If female: she was pregnant or breastfeeding; she had a positive serum pregnancy test; she was of childbearing potential and did not use an accepted effective contraceptive method or she used oral contraceptives.</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>